RxDoctor Payments Data

Roshani Desai, MD

Gastroenterology · Saint Louis, MONPI 1457554834

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,740 of the $50,425 with a category attached, or 84.8%. AbbVie accounts for 98.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $16,599 and has fallen 98.8% since, to $199 in 2025. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,425in general payments, 2019–2025

Across 60 payments — averaging $840.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$49K
  • Intercept Pharmaceuticals, Inc.$440
  • Gilead$174
  • Conmed Corporation$139
  • Ipsen Biopharmaceuticals, Inc$135
  • Sanofi$60
  • plus $76 from 4 others

What the payments were for

  • Speaking & faculty fees$42,74085%
  • Travel & lodging$6,10212%
  • Food & beverage$1,5833%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,425 in reported general payments places this provider in the 90th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$47,916
Medicare patients
166
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin20$64,057
VemlidyTenofovir Alafenamide23$36,018
Ursodiol49$5,435
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl172$2,741
Lactulose31$862
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg38$593
Omeprazole37$571
Spironolactone50$436
ConstuloseLactulose14$377
Pantoprazole Sodium31$343
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$189
Azathioprine11$187
Furosemide56$154
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl11$107
Prednisone23$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$174$36,01823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →